Literature DB >> 3485052

d- and l-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat.

R Invernizzi, C Berettera, S Garattini, R Samanin.   

Abstract

Various doses of fenfluramine isomers were compared for their ability to affect monoamine levels, metabolism and synthesis in the rat brain. d-Fenfluramine was more potent than l-fenfluramine in reducing serotonin (5-HT) and 5-hydroxy-indoleacetic acid (5-HIAA) at 4 h after their administration. After decarboxylase inhibition, a low dose of d-fenfluramine (2.5 mg/kg) reduced 5-HT synthesis, assessed as 5-hydroxytryptophan (5-HTP) accumulation, in the hypotalamus and lower brain-stem only, whereas a higher dose (5 mg/kg) reduced 5-HT synthesis in all brain regions examined except the striatum. A higher dose of l-fenfluramine (10 mg/kg) was required to reduce 5-HT synthesis. Metergoline, a 5-HT antagonist, did not modify the effects of fenfluramine isomers on 5-HT synthesis. One h after its administration l-fenfluramine 5-20 mg/kg significantly increased brain 3-methoxy-4-hydroxyphenylethylene glycol sulfate (MHPG-SO4), striatal homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) levels, while after 4 h only the highest dose raised HVA levels. No change of striatal HVA and DOPAC levels was seen 1 or 4 h after any dose of d-fenfluramine while the highest dose raised brain MHPG-SO4 levels. Neither l- nor d-fenfluramine changed striatal 3-methoxytyramine (3-MT) levels. The noradrenaline (NA) and dopamine (DA) levels were decreased 4 h after 10 and 20 mg/kg l-fenfluramine or 20 mg/kg d-fenfluramine. The results show that the d- and l-isomers of fenfluramine at relatively low doses have a specific action on brain 5-HT and catecholamines, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485052     DOI: 10.1016/0014-2999(86)90633-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  18 in total

1.  Interaction of serotonin- and dopaminergic systems of the brain in mechanisms of latent inhibition in rats.

Authors:  L V Loskutova
Journal:  Neurosci Behav Physiol       Date:  1990 Nov-Dec

2.  Acute and chronic D-fenfluramine treatments have different effects on serotonin synthesis rates in the rat brain: an autoradiographic study.

Authors:  F Yamane; Y Tohyama; M Diksic
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

3.  Platelet monoamine oxidase B (MAO-B) activity and its relationship to DL-fenfluramine-induced prolactin response in healthy men.

Authors:  M Eriksson; U Berggren; C Fahlke; J Engel; J Balldin
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

4.  Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release.

Authors:  C W Callaway; L L Wing; D E Nichols; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Aggression, suicidality, and intermittent explosive disorder: serotonergic correlates in personality disorder and healthy control subjects.

Authors:  Emil F Coccaro; Royce Lee; Richard J Kavoussi
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

6.  The emerging modern face of mood disorders: a didactic editorial with a detailed presentation of data and definitions.

Authors:  Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2010-04-12       Impact factor: 3.455

7.  Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs.

Authors:  T Mennini; A Bizzi; S Caccia; A Codegoni; C Fracasso; E Frittoli; G Guiso; I M Padura; C Taddei; A Uslenghi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

Review 8.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

Review 9.  Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.

Authors:  D McTavish; R C Heel
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

10.  Effects of fenfluramine on plasma homovanillic acid in healthy subjects.

Authors:  E Hollander; D J Stein; J B Saoud; C M DeCaria; T B Cooper; M N Islam; M R Liebowitz; M Stanley
Journal:  J Neural Transm Gen Sect       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.